Cargando…

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

Increasing evidence is emerging that immunotherapeutic interventions, including checkpoint blockade, are predominantly effective in patients with a pre-existing T cell-inflamed tumor microenvironment. Understanding the mechanisms leading to a non-T cell-inflamed microenvironment are crucial for the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spranger, Stefani, Gajewski, Thomas F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570721/ https://www.ncbi.nlm.nih.gov/pubmed/26380088 http://dx.doi.org/10.1186/s40425-015-0089-6

Ejemplares similares

Melanoma-intrinsic β-catenin signaling prevents T cell infiltration and anti-tumor immunity
por: Spranger, Stefani, et al.
Publicado: (2014)

Immune surveillance is thwarted by tumor-cell intrinsic beta-catenin signaling
por: Spranger, Stefani, et al.
Publicado: (2015)

Tumor-intrinsic oncogene pathways mediating immune avoidance
por: Spranger, Stefani, et al.
Publicado: (2015)

β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion
por: Liu, Shenghua, et al.
Publicado: (2018)

A team effort: natural killer cells on the first leg of the tumor immunity relay race
por: Fessenden, Timothy B., et al.
Publicado: (2018)

Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer
por: Sweis, Randy F, et al.
Publicado: (2015)

The Application of Traditional Chinese Medicine Against the Tumor Immune Escape
por: Xu, Jing, et al.
Publicado: (2020)

Hypoxia-Driven Immune Escape in the Tumor Microenvironment
por: Vito, Alyssa, et al.
Publicado: (2020)

Therapeutic efficacy of combined blockade of CTLA-4 +/- PD-L1 +/- IDO is associated with re-activation of T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2013)

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
por: Trujillo, Jonathan A., et al.
Publicado: (2019)

How S. aureus blinds the inflammasome to escape immune control
por: Darisipudi, Murthy N., et al.
Publicado: (2021)

Inhibition of Death Receptor Signaling by Flice-Inhibitory Protein as a Mechanism for Immune Escape of Tumors
por: French, Lars E., et al.
Publicado: (1999)

Omicron: the highly mutational COVID-19 variant with immune escape
por: Khajotia, Rumi
Publicado: (2022)

Modulation of the immune microenvironment by tumor-intrinsic oncogenic signaling
por: Nguyen, Kim Bich, et al.
Publicado: (2019)

Oncogene addiction and immune escape: friends or foes?
por: Abdayem, Pamela, et al.
Publicado: (2020)

Rational combinations of immunotherapeutics that target discrete pathways
por: Spranger, Stefani, et al.
Publicado: (2013)

Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations
por: Di Caro, Antonino, et al.
Publicado: (2021)

Agonistic 4-1bb antibodies in combination with inhibitory antibodies against CTLA-4, PD-L1 or LAG-3 ACT on CD8+ T cells in the tumor microenvironment and synergize to promote regression of established tumors
por: Horton, Brendan, et al.
Publicado: (2014)

The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors
por: Luke, Jason J, et al.
Publicado: (2015)

Agonist anti-4-1BB plus neutralizing anti-CTLA-4 or -PD-L1 synergize to promote tumor regression by rescuing dying dysfunctional CD8+ T cells within the tumor microenvironment
por: Horton, Brendan, et al.
Publicado: (2015)

Successful Aging and Frailty: Mutually Exclusive Paradigms or Two Ends of a Shared Continuum?
por: Cosco, Theodore D., et al.
Publicado: (2015)

The ART of tumor immune escape
por: Wennerberg, Erik, et al.
Publicado: (2022)

Immune Therapy Resistance and Immune Escape of Tumors
por: Seliger, Barbara, et al.
Publicado: (2021)

Commentary: “Baicalein mediates the anti-tumor activity in Osteosarcoma through lncRNA-NEF driven Wnt/β-catenin signaling regulatory axis”
por: Wang, Xinluan
Publicado: (2022)

New insights into the role of EMT in tumor immune escape
por: Terry, Stéphane, et al.
Publicado: (2017)

Mutational escape from CD8(+) T cell immunity: HCV evolution, from chimpanzees to man
por: Bowen, David G., et al.
Publicado: (2005)

Cancer stem cells-driven tumor growth and immune escape: the Janus face of neurotrophins
por: Triaca, Viviana, et al.
Publicado: (2019)

Immunogenicity of cell death driven by immune effectors
por: Galluzzi, Lorenzo, et al.
Publicado: (2020)

A New Paradigm for Evaluating Avoidance/Escape Motivation
por: Tsutsui-Kimura, Iku, et al.
Publicado: (2017)

A new perspective on immune evasion: escaping immune surveillance by inactivating tumor suppressors
por: Mergener, Svenja, et al.
Publicado: (2022)

The paradigm of immune escape by SARS-CoV-2 variants and strategies for repositioning subverted mAbs against escaped VOCs
por: Shah, Masaud, et al.
Publicado: (2022)

Tumor Escape and Progression under Immune Pressure
por: Manjili, Masoud H., et al.
Publicado: (2012)

The Influence of Tumor Microenvironment on Immune Escape of Melanoma
por: Simiczyjew, Aleksandra, et al.
Publicado: (2020)

Biophysics involved in the process of tumor immune escape
por: Wang, Maonan, et al.
Publicado: (2022)

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
por: Spranger, Stefani, et al.
Publicado: (2014)

Interculturalism: Not a new policy paradigm
por: Modood, Tariq
Publicado: (2018)

A new paradigm for the management of ATL
por: Taylor, Graham P., et al.
Publicado: (2022)

Editorial: Tumor-promoting immune cells: Cancer immune escape and beyond
por: Domblides, Charlotte, et al.
Publicado: (2023)

β-Catenin: a transforming actor on many stages
por: Miyoshi, Keiko, et al.
Publicado: (2003)

Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy
por: He, Yunbo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qq1rk9rj0538fpj32e93gqktgb